ASX:PME Pro Medicus (PME) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Pro Medicus Stock (ASX:PME) 30 days 90 days 365 days Advanced Chart Get Pro Medicus alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume285,954 shsAverage VolumeN/AMarket CapitalizationA$29.16 billionP/E Ratio351.99Dividend Yield0.14%Price TargetN/AConsensus RatingN/A Company Overview Pro Medicus Limited engages in the development and supply of healthcare imaging software and services to hospitals, diagnostic imaging groups, and other related health entities in Australia, North America, and Europe. The company offers Visage radiology information systems (RIS), a proprietary medical software for practice management, training, installation, professional services, and after-sale support and service products; and Promedicus.net, an e-health platform. It also provides healthcare imaging software that provides radiologists and clinicians with visualization capability for viewing 2-D, 3-D, and 4-D medical images, as well as picture archive and communication system (PACS)/digital imaging software; and integration products. In addition, the company offers Visage Ease Pro, a mobile application that provides users the ability to interpret various diagnostic imaging studies stored on a Visage 7 server. The company provides its products under the Visage RIS, Visage RIS/PACS, Visage 7, Visage Ease Pro, and Visage Ease names. Pro Medicus Limited was incorporated in 1983 and is headquartered in Richmond, Australia. Read More Receive PME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pro Medicus and its competitors with MarketBeat's FREE daily newsletter. Email Address PME Stock News HeadlinesPME - Pro Medicus Ltd Chart - MorningstarJuly 5 at 10:59 AM | morningstar.comMPro Medicus Ltd (PME) - Investing.com UKJuly 3 at 8:08 PM | uk.investing.comThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.July 5 at 2:00 AM | Crypto Swap Profits (Ad)Why this broker just downgraded Pro Medicus sharesJuly 3 at 8:08 PM | msn.comUP 127% in a year, why is the Pro Medicus share price rocketing higher again today?July 2 at 10:49 PM | msn.comUp 51% since the tariff pain, is it too late to buy Pro Medicus shares?June 17, 2025 | msn.comPro Medicus' (ASX:PME) investors will be pleased with their fantastic 902% return over the last five yearsJune 17, 2025 | finance.yahoo.comPro Medicus Ltd Stock Price HistoryJune 15, 2025 | investing.comSee More Headlines PME Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Pro Medicus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pro Medicus investors own include Mineral Resources (MIN), ResMed (RMD), Technology One (TNE), ARB (ARB), Accent Group (AX1), Cochlear (COH) and CSL (CSL). Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Health Information Services Sub-IndustryN/A Current SymbolASX:PME CIKN/A Webwww.promed.com.au Phone61 3 9429 8800FaxN/AEmployees2,060Year FoundedN/AProfitability EPS (Trailing Twelve Months)A$0.78 Trailing P/E Ratio351.99 Forward P/E RatioN/A P/E Growth3.87Net IncomeA$82.79 million Net Margins51.27% Pretax MarginN/A Return on Equity47.73% Return on Assets30.68% Debt Debt-to-Equity Ratio1.10 Current Ratio5.98 Quick Ratio4.39 Sales & Book Value Annual SalesA$161.50 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow71.76 Book ValueA$1.80 per share Price / BookN/AMiscellaneous Outstanding Shares104,500,000Free FloatN/AMarket CapA$29.16 billion OptionableNot Optionable Beta0.56 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (ASX:PME) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pro Medicus Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Pro Medicus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.